Literature DB >> 3380071

Alphacalcidol and renal function in normal subjects.

E Tvedegaard1, S Madsen.   

Abstract

Sixteen young healthy adults were treated for 3 weeks with alphacalcidol (1 alpha OHD3), 1 microgram orally per day, and renal function tests were performed before, at the end and 3 weeks after termination of the drug. No significant changes occurred in the serum concentrations of calcium or phosphate, whereas the serum calcium-phosphorus product and the urinary excretion of calcium increased significantly. Serum creatinine and the urinary excretion of creatinine showed no significant changes. Inulin clearance decreased by 4% (p = 0.11). The total plasma clearance rate of 51Cr-EDTA and the 24-hour endogenous creatinine clearance both decreased by 4% during the treatment (p less than 0.05). It is concluded that treatment of normal subjects with 1 alpha OHD3, in a modest dose causing no significant change in serum calcium, is associated with a small but reversible decrease in renal function.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3380071

Source DB:  PubMed          Journal:  Miner Electrolyte Metab        ISSN: 0378-0392


  2 in total

1.  Treatment of osteoporosis with vitamin D.

Authors:  J A Kanis; E V McCloskey; D de Takats; J Bernard; D M Zhang
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

2.  A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer.

Authors:  T Gulliford; J English; K W Colston; P Menday; S Moller; R C Coombes
Journal:  Br J Cancer       Date:  1998-07       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.